Clinical trialObservationalCompleted
Clinical Utility Assay as a Biomarker for Gastroenteropancreatic and Lung Neuroendocrine Tumors
The Clinical Utility of a Blood-Based Multitranscriptome Assay as a Biomarker for Gastroenteropancreatic and Lung Neuroendocrine Tumors
- Outcome
- Finished, no results posted
- Phase
- Observational
- Status
- Completed
- Study type
- Observational
- Start
- 9 January 2017
- Ended
- 15 September 2020
- Enrollment
- 105 participants
- Sites
- 1
- Primary outcomes
- Rate of Successful Test Results Per Cohort
- Sponsor type
- Academic / other
- Results posted
- No
- Last update
- 4 August 2021
These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
The purpose of this study is to evaluate how well an investigational blood test performs. The study will look at the sensitivity and specificity of a blood-based multitranscriptome assay (NETest).